Navigation Links
Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
Date:10/21/2008

t

operating performance and a comparison to the Company's past operating

performance.

-- Litigation-related charges - These charges are attributable to

estimated potential losses associated with patent litigation. These

amounts represent significant charges during the third quarter of 2008

and do not reflect expected on-going operating expenses. Accordingly,

management excluded these charges for purposes of calculating these

non-GAAP measures to facilitate an evaluation of the Company's current

operating performance and for comparison to the Company's past

operating performance.

-- Divestiture-related (gains) losses - These amounts represent gains and

losses, and related tax impacts, that the Company recognized related to

the sale of non-strategic assets, including the sale of certain

businesses, development programs and non-strategic investments. The

sale and transfer of these non-strategic assets are expected to be

substantially completed during 2008. These gains and losses are not

indicative of future operating performance and are not used by

management to assess operating performance. Accordingly, management

excluded these amounts for purposes of calculating these non-GAAP

measures to facilitate an evaluation of the Company's current operating

performance and a comparison to the Company's past operating

performance.

-- Intangible asset impairment charges - These amounts represent non-cash

write-downs of certain of the Company's intangible assets. Following

the Company's acquisition of Guidant, and the related increase in the

Company's debt, management has heightened its focus on cash generation

and debt pay down. Management removes the impact of these charges from

the Company's operating performance to assist in assessin
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
2. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
3. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
4. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
5. Boston Scientific to Participate in UBS Global Life Sciences Conference
6. Boston Scientific Announces Court Decision
7. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
8. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
9. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
10. TechCFO Adds Gary Strickland as Partner in Boston Office
11. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at till det ... Science" som hålls i Wien ... undersökning med internationella forskare och vetenskapsmän som ... hälsovetenskapens två största utmaningar bristen på incitament ...
(Date:7/2/2015)... GLEN ELLYN, Ill. , July 2, 2015 /PRNewswire-USNewswire/ ... and Colton Eakins are gaining invaluable real-world ... Institute of Technology this summer. The students ... Dr. Jeff Wereszczynski,s research group at IIT. ... Professors Dr. Tom Carter , Physics; Dr. ...
(Date:7/1/2015)... CA (PRWEB) , ... July 01, 2015 , ... It ... brain injury (TBI) using single photon emission computed tomography (SPECT) according to ... The study, which examined over 20,000 brain scans and is believed to be the ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3COD Students Participate in Prestigious Summer Internships 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... Exchange Symbol: MS, EDMONTON, Nov. 7 /PRNewswire-FirstCall/ ... in the treatment of multiple sclerosis (MS), today,announced ... for the,Company,s phase II MINDSET-01 trial of MBP8298 ... analysis and recommended that,the trial continue as per ...
... affiliate of,Phlo Corporation (OTC: PHLC) (the "Company") announced ... Director of Marketing. Mr. Reynolds is a,marketing and ... in,the United States and Canada. Mr. Reynolds will ... Company, headed by Rudy,Prajza, Chief Marketing Officer. ...
... Therapeutics,Inc. announced today that it has priced its initial ... a price of $10.00 per share. All,shares are being ... the underwriters a 30-day option to purchase up to,an ... common stock will trade on the NASDAQ Global Market ...
Cached Biology Technology:BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2Phlo Affiliate Names Director Of Marketing 2ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering 2
(Date:6/17/2015)... , and HILDEN, Germany , June ... QGEN ; Frankfurt Prime Standard: QIA) today launched new Investigator ... in forensic laboratories in the United States ... to simultaneously analyze multiple key genomic markers (short tandem repeats ... Quality Sensor to evaluate the quality of DNA in ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a ... announced that its U.are.U ® 4500 fingerprint ... Eateries, Inc., a San ... chain, to increase security, improve accountability and reduce ... enable instant, non-repudiable identity confirmation for employee sign ...
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... have helped significantly advance our understanding of the genetic ... over the past year. They are the users of ... of the McGill School of Computer Science and collaborator ... players to contribute to scientific research by arranging multiple ...
... Security Management Systems (SMS) , a leading integrator ... data center security system for Oracle data center ... Based in Somerset, New Jersey, Core ... business operations solutions and information systems, disaster recovery ...
... Leipzig. Europe,s streams will in future be more ... conclusion of a study by the Helmholtz Centre for ... of 1990 with climate and land use change scenarios ... use of insecticides in agriculture will increase significantly in ...
Cached Biology News:Video game players advancing genetic research 2Security Management Systems (SMS) Completes Oracle Data Center Security Project for Core Services Corporation 2Security Management Systems (SMS) Completes Oracle Data Center Security Project for Core Services Corporation 3Insecticides an increasing problem in future for streams in Europe 2Insecticides an increasing problem in future for streams in Europe 3
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... fast emerging as a powerful new tool ... now, only amino groups have been able ... such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and ... additions to the protein interaction tool chest ...
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
...
Biology Products: